GALMED PHARMACEUTICALS LTD. (EOCN) Return on equity 2016–2020
GALMED PHARMACEUTICALS LTD. (EOCN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-65.2%FY2020 · since FY2016: -153.1% → -65.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2020 | -65.2% | -35.9 pp |
| FY2019 | -29.3% | -18.1 pp |
| FY2018 | -11.2% | +66.7 pp |
| FY2017 | -77.9% | +75.2 pp |
| FY2016 | -153.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More EOCN financial trends
EOCN RevenueEOCN Net incomeEOCN Net marginEOCN Gross profitEOCN Gross marginEOCN Operating incomeEOCN Operating marginEOCN Operating cash flowEOCN Free cash flowEOCN Capital expendituresEOCN Stock buybacksEOCN Dividends paidEOCN Total assetsEOCN Total liabilitiesEOCN Shareholders’ equityEOCN overview →